Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use GLP-1 medications
Weeks 12-36 generally represent the fastest fat loss period for most patients
Tirzepatide typically causes less nausea than semaglutidean effect some scientists believe is because the GIP receptor acts like a "buffer" to the nausea caused by activating GLP-1 receptors
In Round 2, 42% agreed that BMI is not the primary concern when considering whether to prescribe SGLT2is versus GLP-1 RAs as first-line therapy, whereas 24% disagreed (34% provided neutral responses)
Some patients experience mild side effects like nausea or gastrointestinal discomfort, which typically subside over time
US$ 22.46
US$ 20.37
US$ 25.04
US$ 25.37
